The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs, And Conference Presentations In The Spotlight

Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow, and follow-on offerings all served to lift stocks higher.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.